Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$6.20M-$6.20MN/M vs Q1 2025 EPS, diluted—
Operating Income-$5,634,000N/M Operating Cash Flow-$5,011,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Free Cash Flowderived
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end